01 April 2010
Aminofeel improves the sensitivity to taste in patients with HCV-infected liver disease
Yumiko NagaoABCDEF, Hisako MatsuokaB, Takumi KawaguchiBF, Michio SataABDEGMed Sci Monit 2010; 16(4): PI7-12 :: ID: 878481
Abstract
Background
Patients with chronic liver diseases have a taste disorder and altered zinc metabolism. We investigated the effects of a supplement enriched with branched-chain amino acids (BCAA) (Aminofeel) on sensitivity to different tastes in patients with hepatitis C virus (HCV) infected liver disease.
Material and Method
Nine patients (mean age 63.3+/-9.1 years) with HCV-related liver diseases were identified and examined for sensitivity to different tastes. Eight patients had no awareness of taste disorders, and 3 patients had oral lichen planus. We examined 4 tastes (sweet, salty, sour, and bitter) using a Taste Disk and sensitivity to different tastes was rated on a 6-point scale (I, II, III, IV, V, and VI). Each patient was given one sachet of Aminofeel after breakfast and another at bedtime for 90 days.
Results
Only one patient was aware of a taste disorder before administration of Aminofeel, but 4 patients had decreased gustatory sensitivity in the sour taste test, and 2 had it in the bitter taste test. Sensitivity to sour tastes significantly increased after the administration of Aminofeel(R) (P=0.03). Sensitivity to sweet tastes increased after the administration of Aminofeel (P=0.06). Zinc value significantly increased after the administration of Aminofeel (P=0.02).
Conclusions
Patients with HCV-infected liver disease have decreased sensitivity to different tastes and decreased zinc levels. Some patients were unaware that they had a taste disorder. Aminofeel improved sensitivity to different tastes and increased zinc values. Thus, Aminofeel is a useful therapeutic agent for taste disorders.
Keywords: Prospective Studies, Liver Diseases - virology, Hepatitis C - virology, Hepacivirus - metabolism, Amino Acids, Branched-Chain - therapeutic use, Taste - drug effects, Taste Disorders - drug therapy
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Animal Research
Role of the Dorsal Cortex of the Inferior Colliculus in the Precedence EffectMed Sci Monit In Press; DOI: 10.12659/MSM.945605
Laboratory Research
Comparative Evaluation of the Dimensional Accuracy of Silicone-Based Putty Reline Impressions with Differen...Med Sci Monit In Press; DOI: 10.12659/MSM.946537
Clinical Research
Ankle-Brachial Index as a Predictor of Acute Ischemic Cerebrovascular Event After Central Retinal Artery Oc...Med Sci Monit In Press; DOI: 10.12659/MSM.945937
Review article
COL3A1 Gene Polymorphism and Its Impact on Female Pelvic Organ ProlapseMed Sci Monit In Press; DOI: 10.12659/MSM.946367
Most Viewed Current Articles
17 Jan 2024 : Review article 6,962,174
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 699,683
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 22,873
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 17,628
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912